Loading...
XNAS
CGEN
Market cap141mUSD
Dec 05, Last price  
1.51USD
1D
-6.21%
1Q
5.59%
Jan 2017
-70.39%
IPO
-86.42%
Name

Compugen Ltd

Chart & Performance

D1W1MN
XNAS:CGEN chart
P/E
—
P/S
5.07
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.07%
Rev. gr., 5y
13.45%
Revenues
28m
-16.72%
646,000215,000180,000338,000250,0001,115,000-424,000242,0003,549,00012,367,0009,277,000712,000017,800,00002,000,0006,000,0007,500,00033,459,00027,864,000
Net income
-14m
L-24.12%
-13,978,000-13,020,000-12,114,000-12,527,000-3,831,000-7,203,000-12,004,000-13,628,000-14,083,000-11,094,000-20,163,000-31,506,000-37,066,000-22,599,000-27,337,000-27,260,000-32,873,000-33,694,000-18,754,000-14,231,000
CFO
50m
P
-11,108,000-9,933,000-8,407,000-10,012,000-7,453,000-4,279,000-9,249,000-10,846,000-6,439,000-11,148,000-25,607,000-19,819,000-30,658,000-13,291,000-27,888,000-28,320,000-22,750,000-34,506,000-35,886,00049,604,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
URL
https://cgen.com/
IPO date
Aug 01, 2000
Employees
69
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT